Solid organ transplantation necessitates the use of lifelong immunosuppression. In particular, the calcineurin inhibitors (CNIs) are utilized in nearly all transplant recipients as they are potent immunosuppressants. In kidney transplantation, the use of CNIs has led to the very low rejection rates of ~7-10% per year. However, long term graft survival has not improved substantially with their utilization, with a mean half-life of 10 years for kidney transplants. A key contributor to late graft injury is CNI-nephrotoxicity which is manifested by declining kidney function and the histological features of interstitial fibrosis, tubular atrophy, and arteriolar hyalinosis. The mechanism by which CNI induce kidney injury and failure is multifactorial, and to date, there are no specific therapeutic strategies to mitigate this injury. The goal of this submission is to identify a novel and clinically applicable strategy to ameliorate CNI-associated kidney injury. Recently, AMP-Activated Protein Kinase (AMPK), a key regulator of cell metabolism, autophagy, and mitochondrial biogenesis, has been linked to modulating kidney injury. Further, loss of AMPK activation is associated with organ inflammation and fibrosis. We hypothesize that AMPK activation could ameliorate some of the adverse metabolic consequences in renal tubular epithelium and as a corollary, AMPK activation could be a clinically relevant intervention to mitigate long term CNI nephrotoxicity. Our study will focus on cyclosporine A (CsA), a classic CNI therapeutic agent. We will utilize a complementary series of studies, both in vitro and in vivo, using a mouse model of CsA injury that we have used successfully in our laboratory. In vitro, we will focus on renal tubular epithelium, the primary target of in vivo injury. We will study both the impact of AMPK activation as well as knock down using pharmacologic agents and silencing RNAs. Outcomes will include assessments of bioenergetics, mitochondrial function, pro-inflammatory markers and the DAMP HMGB1, and paracrine impact on macrophages and their differentiation. In vivo, we will test the impact of AMPK activation on ameliorating CsA renal injury by assessing kidney function (serum creatinine), mRNA expression of inflammatory mediators within the kidney, and biochemical, cellular and histologic assessments of injury and fibrosis. We will assess both pre-emptive inhibition as well as determine the impact of AMPK activation after established CsA nephrotoxicity. To complement these pharmacologic studies, we will also employ the novel use of AMPK ?1 and ?2 deficient mice. Cross-transplant studies will allow us to dissect the role of systemic versus renal expression of AMPK in injury. We believe that this comprehensive approach will provide key mechanistic insights into ameliorating or mitigating CNI nephrotoxicity. The use of a clinically relevant activator, metformin, will provide an opportunity for rapid translation into our human recipients of kidneys and other solid organ transplants.

Public Health Relevance

Solid organ transplantation has revolutionized the care of individuals with organ failure. The VA National Transplant Program, established in 1962, provides transplants, including bone marrow, heart, liver, pancreas, lung and kidneys, to Veterans at 12 VA Medical Centers across the continental US. These individuals all require immunosuppressive medications for their lifetime to avoid rejection of the transplanted organ. Nearly all of these recipients are placed on drugs known as calcineurin inhibitors (CNI). While these drugs are potent immunosuppressives, they are highly toxic to the kidney and lead to kidney failure over time. Current clinical management has included dose reduction or avoidance, but sadly, such strategies have negligible success. This application proposes to study a new mechanism for CNI-caused kidney injury. The study uses both laboratory and mouse models to find a novel and effective therapy to minimize the nephrotoxic effects of these critical immunosuppressive agents and to improve patient outcomes after transplant.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX003272-03
Application #
9605248
Study Section
Nephrology (NEPH)
Project Start
2016-10-01
Project End
2020-09-30
Budget Start
2018-10-01
Budget End
2019-09-30
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Birmingham VA Medical Center
Department
Type
DUNS #
082140880
City
Birmingham
State
AL
Country
United States
Zip Code
35233